9 Meters Biopharma | Investor Presentation Deck | 30 slides

Meters Biopharma · 2022-09
arc beats above · slides in the middle · loops below · scroll → 2 LOOPS
SETUP TENSION ANALYSIS EVIDENCE RESOLUTION APPENDIX
HOVER FOR DETAILS · CLICK A SLIDE FOR FULLSCREEN · STEP 1
No image bound to this slide. Wire up imgproxy to display the rendered slide JPEG.

Deck intelligence map

4
coverage by narrative range · generated from this deck JSON

Slide inventory

30
every slide · same image gating as the playbook
01
Slide 1
The phrase 'one-tract mind' is a pun on the gastrointestinal tract.front_matter
03
The slide uses a stepped process diagram to link scientific focus to business outcomes.inspire_vision
Open slide detailLoop · Golden Circle
04
summarize
Open slide detailLoop · Golden Circle
05
The slide uses a visual connection (lines) to link each executive to a set of company logos representing their past experience.other
06
Uses a Venn diagram to illustrate the intersection of three core business pillars.present_framework
07
The slide uses a Gantt-style visualization to represent clinical trial progress.plan_implementation
08
plan_implementation
09
present_solution
Open slide detailBeat · Solution
10
Includes anatomical comparison of normal vs. SBS GI tract.frame_problem
Open slide detailBeat · ProblemLoop · Cost Of Inaction
11
The slide uses a medical illustration to show the digestive tract and the specific portion of the ileum removed in SBS patients.frame_problem
Open slide detailBeat · ProblemLoop · Cost Of Inaction
12
Uses a path-based diagram to illustrate the progression from diagnosis to long-term outcomes and patient experience.frame_problem
Open slide detailBeat · Solution
13
The slide uses a biological process diagram to illustrate the therapeutic mechanism.present_solution
Open slide detailBeat · Solution
14
Uses a pyramid diagram to illustrate the patient population spectrum for SBS.present_solution
15
The text 'Vurolenatide for short Bowel syndrome Regardless of pArental support requiremeNT' uses an acrostic-like emphasis on letters to spell VIBRANT.transition
16
The title uses an acrostic-style emphasis on letters (V, B, R, A, N) which spells VBRAN, likely a branding or mnemonic device.analyze_data
17
The slide details a 4-group study design with varying dosages of medication vs placebo over a 28-day treatment period.plan_implementation
18
The table displays N, sex, age, weight, race, ethnicity, and surgical status for placebo and three treatment arms.analyze_data
19
The chart compares placebo, 50 mg Q2W, 50 mg weekly, and 100 mg Q2W groups, highlighting percentage decreases relative to the placebo increase.analyze_data
Open slide detailBeat · Traction
20
The chart displays clinical trial data for 9Meters Biopharma, showing efficacy of the 50mg Q2W dosage.show_traction
Open slide detailBeat · Traction
21
The chart displays clinical trial data for three small cohorts (n=3 each).show_traction
Open slide detailBeat · Traction
22
The slide highlights the efficacy of the 50 mg Q2W dose compared to other cohorts.show_traction
Open slide detailBeat · Traction
23
TSO likely refers to a specific clinical biomarker or symptom score.show_traction
Open slide detailBeat · Traction
24
The chart illustrates the 'stacking effect' (undesirable accumulation) in the 50 mg weekly and 100 mg Q2W groups, contrasting them with the 50 mg Q2W group whicpresent_solution
25
The slide highlights a secondary endpoint result for a specific subset of patients.show_traction
26
The table displays counts of specific adverse events (Nausea, Vomiting, etc.) across four study arms.analyze_data
27
The slide uses checkmarks to denote key achievements/findings.show_traction
28
plan_implementation
Open slide detailBeat · Next Steps
29
plan_implementation
Open slide detailBeat · Next Steps
30
This is a contact/closing slide.other